Oaktree Acquisition Corp. III Life Sciences (OACCU) — SEC Filings
Oaktree Acquisition Corp. III Life Sciences (OACCU) — 16 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 8 8-K, 3 10-Q, 2 SC 13G.
View Oaktree Acquisition Corp. III Life Sciences on SEC EDGAR
Overview
Oaktree Acquisition Corp. III Life Sciences (OACCU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Oaktree Acquisition Corp. III Life Sciences (OACCU) reported a net income of $1,966,742 for the three months ended September 30, 2025, a significant improvement from a net loss of $48,095 in the same period of 2024. For the nine months ended September 30, 2025, the company posted a net income of $5,
Sentiment Summary
Across 16 filings, the sentiment breakdown is: 15 neutral, 1 mixed. The dominant filing sentiment for Oaktree Acquisition Corp. III Life Sciences is neutral.
Filing Type Overview
Oaktree Acquisition Corp. III Life Sciences (OACCU) has filed 3 10-Q, 8 8-K, 1 10-K, 2 SC 13G, 1 S-1/A, 1 S-1 with the SEC between Oct 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (16)
Risk Profile
Risk Assessment: Of OACCU's 14 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $5,499,876 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $199,769,089 |
| Operating Margin | N/A |
| Total Assets | $201,249,963 |
| Total Debt | $8,245,536 |
Key Executives
- Zaid Pardesi
- Christian O. Nagler, P.C.
- Peter S. Seligson, P.C.
- Mathieu Kohmann
Industry Context
Oaktree Acquisition Corp. III Life Sciences operates within the dynamic and highly competitive life sciences sector. This industry is characterized by rapid innovation, significant research and development investment, and stringent regulatory oversight. SPACs like OACCU aim to capitalize on this by identifying promising private companies for acquisition, providing them with access to public markets.
Top Tags
spac (6) · life-sciences (4) · SPAC (3) · corporate-governance (3) · filing (3) · Life Sciences (2) · 10-Q (2) · Blank Check Company (2) · Trust Account (2) · Net Income (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income (Q3 2025) | $1,966,742 | Significant swing from a $48,095 net loss in Q3 2024. |
| Net Income (YTD Q3 2025) | $5,499,876 | Driven by interest income, compared to a $48,095 net loss in the prior year period. |
| Interest Income (YTD Q3 2025) | $6,440,067 | Primary source of profitability, earned on Trust Account funds. |
| Cash in Trust Account | $199,769,089 | As of September 30, 2025, representing the capital available for a Business Combination. |
| General & Administrative Expenses (YTD Q3 2025) | $940,191 | Increased from $48,095 in the prior year, reflecting ongoing operational costs. |
| Class A Ordinary Shares Subject to Redemption | 19,199,029 | As of September 30, 2025, at a redemption value of $10.41 per share. |
| Redemption Value per Class A Share | $10.41 | As of September 30, 2025, up from $10.08 at December 31, 2024, due to accrued interest. |
| Due to Related Party | $710,857 | Increased from zero at December 31, 2024, indicating increased sponsor support or advances. |
| SEC File Number | 001-42383 | Identifies the company's filing with the SEC. |
| Net Income (Q2 2025) | $1,874,343 | Generated from interest on Trust Account, offsetting G&A expenses. |
| Net Income (YTD Q2 2025) | $3,533,134 | Primarily from interest earned on Trust Account funds. |
| Interest Earned on Trust Account (YTD Q2 2025) | $4,247,746 | Main source of non-operating income for the period. |
| Total Liabilities | $8,137,983 | Increased from $7,746,071 at Dec 31, 2024, partly due to related party debt. |
| Business Combination Period | 24 months | Deadline from IPO (October 25, 2024) to complete an acquisition or liquidate. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Oaktree Acquisition Corp. III Life Sciences (OACCU)?
Oaktree Acquisition Corp. III Life Sciences has 16 recent SEC filings from Oct 2024 to Nov 2025, including 8 8-K, 3 10-Q, 2 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OACCU filings?
Across 16 filings, the sentiment breakdown is: 15 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Oaktree Acquisition Corp. III Life Sciences SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Oaktree Acquisition Corp. III Life Sciences (OACCU) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Oaktree Acquisition Corp. III Life Sciences?
Key financial highlights from Oaktree Acquisition Corp. III Life Sciences's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OACCU?
The investment thesis for OACCU includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Oaktree Acquisition Corp. III Life Sciences?
Key executives identified across Oaktree Acquisition Corp. III Life Sciences's filings include Zaid Pardesi, Christian O. Nagler, P.C., Peter S. Seligson, P.C., Mathieu Kohmann.
What are the main risk factors for Oaktree Acquisition Corp. III Life Sciences stock?
Of OACCU's 14 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Oaktree Acquisition Corp. III Life Sciences?
Forward guidance and predictions for Oaktree Acquisition Corp. III Life Sciences are extracted from SEC filings as they are enriched.